Application of Emulsion Technology to Transarterial Injection Chemotherapy for Hepatocellular Carcinoma Using Double-Emulsion Enclosing Vesicles of Anticancer Drug Solution

2007 ◽  
pp. 257-274
Author(s):  
Shushi Higashi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Anticancer Drug ◽  
Double Emulsion ◽  
Drug Solution

Transcatheter arterial embolization using iodized oil (lipiodol) mixed with an anticancer drug for the treatment of hepatocellular carcinoma

1989 ◽  
Vol 23 (S1) ◽  
pp. S33-S36 ◽  
Author(s):  
Hajime Ohishi ◽  
Hitoshi Yoshimura ◽  
Hideo Uchida ◽  
Hiroshi Sakaguchi ◽  
Tetsuya Yoshioka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Anticancer Drug ◽  
Transcatheter Arterial Embolization ◽  
Arterial Embolization ◽  
Iodized Oil

CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma

2019 ◽  
Vol 20 (15) ◽  
pp. 1085-1092 ◽  
Author(s):  
Volker M Lauschke ◽  
Åsa Nordling ◽  
Yitian Zhou ◽  
Sara Fontalva ◽  
Isabel Barragan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Resistance ◽  
Anticancer Drug ◽  
Liver Tumors ◽  
Relative Increase ◽  
Loss Of Function ◽  
Wide Range ◽  
Peritumoral Tissue ◽  
Anticancer Drug Resistance ◽  
The Relationship

Recently, it was published that CYP3A5 contributes to chemotherapeutic drug resistance in a wide range of solid tumors, including hepatocellular carcinoma. However, CYP3A5 is highly polymorphic and 90% of Caucasians are homozygous for the loss-of-function allele CYP3A5*3. Here, we evaluate the relationship between CYP3A5 genotype and expression level of both CYP3A5 transcripts and protein in biopsies from 19 pairs of liver tumors and corresponding peritumoral tissue. We find that CYP3A5 transcript levels are reduced compared with peritumoral controls. Moreover, we do not detect CYP3A5 protein in homozygous CYP3A5*3 carriers and no relative increase of CYP3A5 in tumoral tissue of CYP3A5*1 carriers. We conclude that anticancer drug resistance is unlikely to be caused by increased CYP3A5 expression.

Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity

2018 ◽  
Vol 54 (87) ◽  
pp. 12353-12356 ◽  
Author(s):  
Hardev Singh ◽  
Seo Jin Kim ◽  
Dong Hoon Kang ◽  
Hye-Ri Kim ◽  
Amit Sharma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Delivery ◽  
Drug Delivery System ◽  
Anticancer Drug ◽  
Delivery System ◽  
Small Molecule ◽  
Glycyrrhetinic Acid ◽  
Active Targeting ◽  
Cell Type ◽  
Anticancer Drug Delivery

Herein, we explore glycyrrhetinic acid (GA) as an active targeting ligand for hepatocellular carcinoma (HCC) using a small molecule approach.

scholarly journals An Impression of Clinical Application of a New Oil-Soluble Intraarterial Anticancer Drug Miliplatin for Hepatocellular Carcinoma

2011 ◽  
Vol 140 (5) ◽  
pp. S-597 ◽  
Author(s):  
Keisuke Hamamura ◽  
Takahiro Kondo ◽  
Kengo Kuroishi ◽  
Naohiro Nakamura ◽  
Ryo Suzuki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Application ◽  
Anticancer Drug

Lipid response of hepatocellular carcinoma cells to anticancer drug detected on nanostructure-assisted LDI-MS platform

Talanta ◽  
2021 ◽  
pp. 122817
Author(s):  
Tao Wang ◽  
Xingyue Liu ◽  
Xuetong Qu ◽  
Yuexin Li ◽  
Xiao Liang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Anticancer Drug ◽  
Carcinoma Cells ◽  
Hepatocellular Carcinoma Cells ◽  
Lipid Response
Sign in / Sign up

Export Citation Format

Share Document